Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24793362 | 0.90 | BTN3A1 (0.41) | BTN3A1SMN1; SMN2KCNA5CASP1 | |
| SCHEMBL24793363 | 0.86 | BTN3A1 (0.43) | BTN3A1CASP1 | |
| SCHEMBL22066284 | 0.81 | BTN3A1 (0.42) | BTN3A1SMN1; SMN2CASP1 | |
| SCHEMBL18973558 | 0.80 | BTN3A1 (0.49) | BTN3A1KCNA5 | |
| SCHEMBL22066280 | 0.79 | BTN3A1 (0.47) | BTN3A1CASP1 | |
| SCHEMBL22065039 | 0.78 | BTN3A1 (0.51) | BTN3A1CASP1 | |
| SCHEMBL20587649 | 0.78 | BTN3A1 (0.42) | BTN3A1SMN1; SMN2CASP1 | |
| SCHEMBL22065060 | 0.78 | BTN3A1 (0.42) | BTN3A1SMN1; SMN2CASP1 | |
| SCHEMBL20833545 | 0.78 | BTN3A1 (0.42) | BTN3A1SMN1; SMN2CASP1 | |
| SCHEMBL30435500 | 0.78 | BTN3A1 (0.42) | BTN3A1SMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | TACR1 3171/4885BTN3A1 4531/4885SMN1; SMN2 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.